mRNA transfection retrofits cell-based assays with xenobiotic metabolism

Bull, 2001, A genetically engineered cell-based system for detecting metabolism-mediated toxicity, Altern. Lab. Anim, 29, 703, 10.1177/026119290102900601 Chauret, 1998, Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes, Drug Metab. Dispos., 26, 1 2010 Dean, 2012, Amitriptyline therapy and CYP2D6 and CYP2C19 genotype Diebold, 2004, Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA, Science, 303, 1529, 10.1126/science.1093616 Doehmer, 1993, V79 Chinese hamster cells genetically engineered for cytochrome P450 and their use in mutagenicity and metabolism studies, Toxicology, 82, 105, 10.1016/0300-483X(93)90063-X Donato, 2008, Cell lines: A tool for in vitro drug metabolism studies, Curr. Drug Metab., 9, 1, 10.2174/138920008783331086 Garcia-Canton, 2013, Metabolic characterization of cell systems used in in vitro toxicology testing: lung cell system BEAS-2B as a working example, Toxicol. in Vitro, 27, 1719, 10.1016/j.tiv.2013.05.001 Gotz, 2012, Xenobiotic metabolism capacities of human skin in comparison with a 3D epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: activating enzymes (Phase I), Exp. Dermatol., 21, 358, 10.1111/j.1600-0625.2012.01486.x Hodgson, 2007, Human metabolic interactions of environmental chemicals, J. Biochem. Mol. Toxicol., 21, 182, 10.1002/jbt.20175 Ioannides, 2004, Cytochromes P450 in the bioactivation of chemicals, Curr. Top. Med. Chem., 4, 1767, 10.2174/1568026043387188 Jackson, 2016, Contextualizing hepatocyte functionality of cryopreserved HepaRG cell cultures, Drug Metab. Dispos., 44, 1463, 10.1124/dmd.116.069831 Jacobs, 2013, In vitro metabolism and bioavailability tests for endocrine active substances: what is needed next for regulatory purposes?, ALTEX, 30, 331, 10.14573/altex.2013.3.331 Jewell, 1995, Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine, Xenobiotica, 25, 199, 10.3109/00498259509061845 Kirkland, 2007, How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop, Mutat. Res., 628, 31, 10.1016/j.mrgentox.2006.11.008 Kitamura, 1992, Stable expression of cytochrome P450IIIA7 cDNA in human breast cancer cell line MCF-7 and its application to cytotoxicity testing, Arch. Biochem. Biophys., 292, 136, 10.1016/0003-9861(92)90061-Z Lengler, 2006, Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy, Biochem. Pharmacol., 72, 893, 10.1016/j.bcp.2006.06.012 Mace, 1997, Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines, Carcinogenesis, 18, 1291, 10.1093/carcin/18.7.1291 Mollergues, 2017, Incorporation of a metabolizing system in biodetection assays for endocrine active substances, ALTEX, 34, 389, 10.14573/altex.1611021 OECD: Organisation for Economic Co-operation and Development, 2008, 1 Preskey, 2016, Synthetically modified mRNA for efficient and fast human iPS cell generation and direct transdifferentiation to myoblasts, Biochem. Biophys. Res. Commun., 473, 743, 10.1016/j.bbrc.2015.09.102 Reigh, 1996, Cytochrome P450 species involved in the metabolism of quinoline, Carcinogenesis, 17, 1989, 10.1093/carcin/17.9.1989 Riddick, 2013, NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology, Drug Metab. Dispos., 41, 12, 10.1124/dmd.112.048991 2001 Slatter, 2006, Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome, Xenobiotica, 36, 938, 10.1080/00498250600861728 Soltanpour, 2012, Characterization of THLE-cytochrome P450 (P450) cell lines: gene expression background and relationship to P450-enzyme activity, Drug Metab. Dispos., 40, 2054, 10.1124/dmd.112.045815 Thomas, 2012, A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening, Toxicol. Sci., 128, 398, 10.1093/toxsci/kfs159 Vignati, 2005, An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics, Toxicology, 216, 154, 10.1016/j.tox.2005.08.003 Walsky, 2004, Validated assays for human cytochrome P450 activities, Drug Metab. Dispos., 32, 647, 10.1124/dmd.32.6.647 Warren, 2010, Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA, Cell Stem Cell, 7, 618, 10.1016/j.stem.2010.08.012 Westerink, 2007, Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells, Toxicol. in Vitro, 21, 1581, 10.1016/j.tiv.2007.05.014 Xuan, 2016, Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity, Chem. Biol. Interact., 255, 63, 10.1016/j.cbi.2015.10.009 Zanger, 2013, Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation, Pharmacol. Ther., 138, 103, 10.1016/j.pharmthera.2012.12.007